HDAC6 and plasma cell myeloma: HDAC6 inhibitor ACY-1215 has progressed to phase I/II clinical trials, but was associated with unfavourable pharmacokinetic properties.17,38 This outcome was potentially resolved with orally bioavailable compound WT161 that showed promise in combination with bortezomib in a pre-clinical model of multiple myeloma.17 To our knowledge, our study is the first to describe a strategy of tackling protein homeostasis in order to treat solid tumours.